Exelixis

Research only

EXEL · Tracked drugs and regulatory events

Tracked programs

1 program

metastatic colorectal cancer

Publication and retrieval dates are shown separately. Market rules determine which evidence can resolve an outcome.

sec-filingwww.sec.gov

Filing reports an extended review for zanzalintinib plus atezolizumab, with a March 3, 2027 target.

sponsor-sciencewww.exelixis.com

Sponsor places zanzalintinib within its small-molecule discovery portfolio.

Registry identifies the associated compound, condition and sponsor; trial completion is separate from FDA action.